ERAS® USA Chapter and Pacira BioSciences Launch Collaborative to Implement Enhanced Recovery after Surgery Protocols at Hospitals Across the Country

The initiative aims to increase utilization of evidence-based practice pathways, through monitoring of compliance and outcomes, including utilization of standardized opioid-sparing multimodal pain management strategies

BEVERLY, Mass., July 29, 2019 – ERAS® USA, the official Chapter of ERAS® International Society, an interdisciplinary organization founded to improve perioperative care and enhance postoperative recovery, and Pacira BioSciences, Inc., a leading provider of innovative non-opioid pain management options, announced today a new collaboration dedicated to the improvement of postsurgical patient outcomes, including the reduction of reliance on opioids. The initiative will utilize all U.S. based hospitals that are accredited by ERAS® International Society as Centers of ERAS® Excellence to train healthcare institutions across the country on the proper implementation and monitoring of enhanced recovery after surgery pathways.

Using multispecialty training teams consisting of surgeons, anesthesiologists, advanced practice provider coordinators, nurse coordinators, information technologists and administrators, U.S. based Centers of ERAS® Excellence will deliver to select hospitals the formal ERAS® Implementation Program that consists of a series of structured onsite training seminars. The curriculum incorporates the most current updates on service specific ERAS® pathways, including goal-directed resuscitation, opioid-sparing multimodal pain management strategies, drain management, and best practices in abdominal wall and other field blocks. It also includes a critical view on financial implications, with special attention to business planning and fee for value optimization. Finally, it includes real life “how to” sessions for a successful ERAS® implementation that focus on the collaboration among administrators, physicians, nurses and the rest of health care professionals. All participating hospitals, upon successful completion of the training program, will receive by ERAS® International Society the designation of ERAS® Qualified Center.

“The ERAS® Implementation Programs delivered by the U.S. based centers since 2017 are in accordance with the standards and training practices that ERAS® International Society has followed for more than 10 years throughout the world in over 200 hospitals” said Dionisios
Vrochides, MD, PhD, President of ERAS® USA Chapter, a liver & pancreas surgeon and Vice Chair of Quality and Outcomes for the Department of Surgery at Atrium Health, in Charlotte, NC.

In addition, hospitals being trained by ERAS® USA Chapter will also receive the ERAS® Interactive Audit System, a web-based, secure, and compliant data entry and analysis system to facilitate implementation, widespread dissemination, and compliance with ERAS® protocols. The tool is a quality and decision support system capable of giving immediate feedback regarding any deviation from best practices.

“We are excited and proud to partner with ERAS® USA Chapter on this important endeavor to deploy procedure-specific enhanced recovery protocols to hospitals across the country, reducing reliance on opioid use, and improving the postsurgical recovery process for patients,” said Dave Stack, Chairman and Chief Executive Officer of Pacira. The program will launch to prospective hospitals in the third quarter of 2019.

About ERAS® USA Chapter
ERAS® USA, a chapter of ERAS Society, was founded in 2016 with the mission to improve perioperative care and to enhance postoperative recovery through implementation of evidence-based practice, audit, education, and research. Central to this mission is a culture of inclusivity and recognition of the importance of multi-professional and multi-disciplinary collaboration. As a part of its effort to improve patient care as such, ERAS USA facilitates the training of multi-specialty teams lead by regional ERAS® Centers of Excellence through the ERAS® Implementation Program (EIP) and ERAS® Interactive Audit System (EIAS).

About Pacira BioSciences
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.